Focus Investment Banking

JUNE 13, 2023

As we’ve seen in other healthcare verticals, PE interest is driven by the opportunity to provide growth capital, contribute management expertise, and consolidate a fragmented industry to increase efficiency. Founded in 2007, publicly-traded TOI provides care to about 1.8 Alliance Health Services. Tahoe still owns a minority interest.

Hospitality 52

Hospitality Private Equity Mergers and Acquisitions Medical 52

Software Equity Group

MARCH 13, 2023

In terms of the target market, the top five SaaS verticals were led by Healthcare, as more and more companies in the healthcare sector turn to SaaS solutions to improve patient care and manage costs. Strategic buyers are publicly traded or privately owned software companies. In 2022, verticals made up 42%, a slight increase.

M&A 52

M&A Private Equity Equities S&P 52

Software Equity Group

MAY 7, 2024

The most active verticals in 2023 were Healthcare, Financial Services, and Real Estate. Healthcare has remained the most active vertical (17% of vertical SaaS deals), driven by the essential nature of healthcare operations regardless of economic climate. It’s partly a matter of perception. in 4Q23, up 31% YOY against 4Q22.

M&A 52

M&A Valuation Economics Business 52

Software Equity Group

MAY 8, 2024

The most active verticals in 2023 were Healthcare, Financial Services, and Real Estate. Healthcare has remained the most active vertical (17% of vertical SaaS deals), driven by the essential nature of healthcare operations regardless of economic climate. It’s partly a matter of perception. in 4Q23, up 31% YOY against 4Q22.

M&A 52

M&A Valuation Economics Business 52

Cooley M&A

OCTOBER 29, 2020

Although an IPO and a de-SPAC transaction both result in the target’s stockholders owning equity in a publicly-traded company, it is very possible that a target’s existing governance documents, including stockholders agreements, do not account for a de-SPAC transaction in the way that they would an IPO. Revisiting Governance Documentation.

M&A 52

M&A IPO Valuation Mergers and Acquisitions 52

Cooley M&A

JANUARY 25, 2023

Novartis announced plans to spin off its generics and biosimilars division into a publicly traded stand-alone company. 2022 was the busiest year for activism in the past four years, and the healthcare and life sciences industry was no exception.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 20, 2022

For example, early in 2021, Zimmer Biomet Holdings announced that it would spin off its spine and dental businesses into a new publicly traded company as a way to “optimize resource allocation” among its remaining businesses. Of the 20 largest public deals in the healthcare sector in 2021, 14 featured all?cash 30, 2021. [8]

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

Convergence of tech and healthcare drives digital health deals As discussed in our 2022 Life Sciences M&A Year in Review blog post , decreased valuations and challenging capital markets also impacted healthcare companies last year, and digital health companies – health companies that build and sell technology – were no exception.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Focus Investment Banking

DECEMBER 20, 2024

to a strategic buyer confirms the value retina practices hold for healthcare investors and operators. Cencora, one of the largest publicly-traded pharmaceutical companies in the world, distributes pharmaceuticals, over-the-counter healthcare products and other healthcare supplies and equipment to healthcare providers.

Private Equity 52

Private Equity Healthcare Equities Sale 52

Focus Investment Banking

FEBRUARY 11, 2025

Traditional terminal exit routes for private equity-backed companies are to larger strategic acquirers (often public companies) and IPOs, where a private company becomes publicly traded. However, the type of larger company that would be interested in buying physician practice management (PPM) companies has been unknown. dental).

Private Equity 52

Private Equity Healthcare Equities Medical 52

Cooley M&A

JANUARY 22, 2025

Public company deals: Smaller bites in more focused therapeutic areas The landscape for public company sales in the life sciences sector in 2024 was notably quieter than expected, with anticipated high-profile deals failing to materialize. 2] Novo Holdings $16.5

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64